Clinical trials: Intracerebral Haemorrhage (ICH)
Intracerebral Hemorrhage (ICH)
Safety Study of CN-105 Neuroprotective Peptide for Intracerebral Hemorrhage
This study evaluates the safety, tolerability, and pharmacokinetics (PK) of a single escalating dose and repeated doses of CN-105 in healthy adult participants. There will be about 48 subjects, 36 active and 12 placebo.
- Trial name
- NCT02670824
- Testing
- CN-105
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AegisCN LLC
Intracerebral Hemorrhage
AI ENRICH - AI Detection of ICH
To evaluate the performance of the Viz RECRUIT software in subjects identified as symptomatic of a stroke event as determined by standard of care imaging assessments and interpretation.
- Trial name
- NCT03865979
- Testing
- Viz RECRUIT
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- Viz.ai, Inc.
Intracerebral Hemorrhage
Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
This study will determine if NXY-059 is safe in patients with an acute stroke caused by bleeding in the central nervous system. The primary objective was to assess the safety and tolerability of NXY-059 compared to placebo.
- Trial name
- NCT00075959
- Testing
- NXY-059
- Where
- 64 sites in United States
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Hemorrhagic Stroke, Intracerebral Hemorrhage (ICH)
Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH).
This is a randomized, placebo-controlled, subject and investigator-blinded study to evaluate efficacy, safety and tolerability of BAF312 in participants with intracerebral hemorrhage (ICH)
- Trial name
- NCT03338998
- Testing
- BAF312 solution, BAF312 tablet
- Where
- 11 sites in United States
- Volunteers
- 32 people
- Sponsor
- Novartis Pharmaceuticals
Intracerebral Hemorrhage, Cerebral Hemorrhage
ENRICH: Early MiNimally-invasive Removal of IntraCerebral Hemorrhage (ICH)
This is a multicenter, randomized, adaptive clinical trial comparing standard medical management to early (<24 hours) surgical hematoma evacuation using minimally invasive parafascicular surgery (MIPS) in the treatment of acute…
- Conditions
- Intracerebral Hemorrhage, Cerebral Hemorrhage, Intracerebral Haemorrhage
- Trial name
- ENRICH (NCT02880878)
- Testing
- Early Surgical Hematoma Evacuation
- Where
- 36 sites in United States
- Volunteers
- 300 people
- Sponsor
- Nico Corporation
Intracerebral Hemorrhage, Cerebral Hemorrhage
MIECH: The Minimally Invasive Endoscopic Surgery With the Axonpen System for Spontaneous Intracerebral Hemorrhage
The primary objective of this trial is to provide preliminary safety data of minimally invasive endoscopic surgery using the Axonpen™ system for spontaneous intracerebral hemorrhage (ICH).
- Conditions
- Intracerebral Hemorrhage, Cerebral Hemorrhage, Intracranial Hemorrhage, Basal Ganglia Hemorrhage
- Trial name
- NCT04839770
- Testing
- Axonpen system
- Where
- Taiwan
- Volunteers
- 10 people
- Sponsor
- Clearmind Biomedical Inc.
Acquired Bleeding Disorder, Intracerebral Haemorrhage
Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage
This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the safety and preliminary efficacy of activated recombinant human factor VII (NovoSeven®) for preventing early hematoma growth…
- Trial name
- NCT01563445
- Testing
- activated recombinant human factor VII
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Novo Nordisk A/S
Intracerebral Hemorrhage
ADVANCE- Automated Detection and Volumetric Assessment of ICH
To evaluate the performance of the Viz ICH VOLUME algorithm.
- Trial name
- NCT04733638
- Testing
- Viz ICH VOLUME
- Where
- 5 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Viz.ai, Inc.
Intracerebral Hemorrhage (ICH)
GLP-1 CellBeads® for the Treatment of Stroke Patients With Space-occupying Intracerebral Hemorrhage
The objective of this study is to assess the safety of GLP-1 CellBeads® in patients with space-occupying intracerebral hemorrhage.
- Trial name
- NCT01298830
- Testing
- GLP-1 CellBeads
- Where
- 6 sites in Germany
- Volunteers
- 11 people
- Sponsor
- CellMed AG, a subsidiary of BTG plc.
Intracerebral Hemorrhage
A Proof of Concept Study to Evaluate CN-105 in ICH Patients
A multicenter, open-label phase 2a trial of CN-105 in patients with supratentorial intracerebral hemorrhage (ICH). Patients will be evaluated for eligibility within 12 hours of symptom onset.
- Trial name
- CATCH (NCT03168581)
- Testing
- CN-105
- Where
- 5 sites in United States
- Volunteers
- 38 people
- Sponsor
- AegisCN LLC
Cerebral Hemorrhage, Brain Hemorrhage
MIND: Artemis in the Removal of Intracerebral Hemorrhage
The primary objective of this multicenter randomized controlled study is to compare the safety and efficacy of minimally invasive hematoma evacuation with the Artemis Neuro Evacuation Device to best medical management for the…
- Conditions
- Cerebral Hemorrhage, Brain Hemorrhage, Cerebral Parenchymal Hemorrhage, Intracerebral Hemorrhage
- Trial name
- NCT03342664
- Testing
- Artemis + Medical Management, Best Medical Management Alone (MM)
- Where
- 33 sites in United States, Austria and 2 more
- Volunteers
- 236 people
- Sponsor
- Penumbra Inc.
Intracerebral Hemorrhage
Safety and Tolerability of PF-05230907 in Intracerebral Hemorrhage
This study employs a modified continual reassessment method (mCRM) design to estimate the maximum tolerated dose (MTD) of PF-05230907, defined as a target toxicity rate of 15% based on treatment emergent thromboembolic and/or…
- Trial name
- NCT02687191
- Testing
- PF-05230907
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 21 people
- Sponsor
- Pfizer
Intracerebral Hemorrhage
A Study to Evaluate the Safety, Tolerability and the Effects of Ixodes Ricinus-Contact Phase Inhibitor (Ir-CPI) in Adult Patients With Spontaneous Intracerebral Haemorrhage
The purpose of the study is to provide a first assessment of safety, tolerability and efficacy of Ir-CPI, administered on top of standard-of-care, on secondary brain injury in patients with spontaneous intracerebral haemorrhage.
- Trial name
- BIRCH (NCT05970224)
- Testing
- Ir-CPI
- Where
- 8 sites in Belgium
- Volunteers
- 23 people
- Sponsor
- Bioxodes S.A.